Related Experiment Video
Updated: Apr 29, 2026
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
Patient-derived xenograft models in gynecologic malignancies
Clare L Scott1, Helen J Mackay1, Paul Haluska1
1From The Walter and Eliza Hall Institute of Medical Research and Royal Women's Hospital, Parkville, Victoria, Australia; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada; Department of Oncology, Mayo Clinic, Rochester, MN.
Abstract:
In the era of targeted therapies, patients with gynecologic malignancies have not yet been major beneficiaries of this new class of agents. This may reflect the fact that the main tumor types-ovarian, uterine, and cervical--are a highly heterogeneous group of cancers with variable response to standard chemotherapies and the lack of models in which to study the diversity of these cancers. Cancer-derived cell lines fail to adequately recapitulate molecular hallmarks of specific cancer subsets and complex microenvironments, which may be critical for sensitivity to targeted therapies. Patient-derived xenografts (PDX) generated from fresh human tumor without prior in vitro culture, combined with whole genome expression, gene copy number, and sequencing analyses, could dramatically aid the development of novel therapies for gynecologic malignancies. Gynecologic tumors can be engrafted in immunodeficient mice with a high rate of success and within a reasonable time frame. The resulting PDX accurately recapitulates the patient's tumor with respect to histologic, molecular, and in vivo treatment response characteristics. Orthotopic PDX develop complications relevant to the clinic, such as ascites and bowel obstruction, providing opportunities to understand the biology of these clinical problems. Thus, PDX have great promise for improved understanding of gynecologic malignancies, serve as better models for designing novel therapies and clinical trials, and could underpin individualized, directed therapy for patients from whom such models have been established.
Insights
Patient-derived xenografts (PDX) offer a promising solution for gynecologic cancer research. These models accurately reflect patient tumors, aiding the development of targeted therapies and personalized treatment strategies.
Area of Science:
- Oncology
- Translational Research
- Gynecologic Oncology
Background:
- Gynecologic malignancies (ovarian, uterine, cervical) are heterogeneous and poorly responsive to current targeted therapies.
- Existing cancer cell lines do not fully represent tumor diversity or microenvironments crucial for targeted therapy response.
- There is a critical need for better preclinical models to advance gynecologic cancer treatment.
Purpose of the Study:
- To evaluate patient-derived xenografts (PDX) as a superior model for gynecologic malignancies.
- To demonstrate the utility of PDX in understanding tumor heterogeneity and developing novel therapies.
- To highlight the potential of PDX for advancing personalized medicine in gynecologic cancers.
Main Methods:
- Generation of PDX models from fresh human gynecologic tumors without prior in vitro culture.
- Comprehensive molecular profiling of PDX, including whole genome expression, gene copy number, and sequencing.
- Engraftment of gynecologic tumors in immunodeficient mice, including orthotopic implantation.
- Assessment of PDX for recapitulation of patient tumor histology, molecular features, and treatment response.
Main Results:
- High success rate and reasonable time frame for generating gynecologic PDX models.
- PDX models accurately recapitulate patient tumor characteristics (histologic, molecular, in vivo response).
- Orthotopic PDX models develop clinically relevant complications like ascites and bowel obstruction.
Conclusions:
- PDX models provide a powerful tool for understanding gynecologic cancer biology and heterogeneity.
- PDX serve as more effective preclinical models for designing novel therapies and clinical trials.
- PDX models hold significant promise for advancing individualized, targeted therapy for gynecologic malignancies.
